Vasilios J. Assikis, MD

Articles by Vasilios J. Assikis, MD

Risks and Benefits of Tamoxifen Therapy

ByVasilios J. Assikis, MD,V. Craig Jordan, OBE, PhD, DSc

February 1st 1997

Tamoxifen is the most widely prescribed endocrine therapy for breast cancer, with more than 7.5 million woman-years of clinical experience. Tamoxifen has both antiestrogenic and estrogenic activity. The antiestrogenic activity

Latest Updated Articles

Risks and Benefits of Tamoxifen Therapy
February 1st 1997

Trending on CancerNetwork

124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis